EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback

Nathaniel Bloom, Sydney I Ramirez, Hallie Cohn, Urvi M Parikh, Amy Heaps, Scott F Sieg, Alex Greninger iD, Justin Ritz, Carlee Moser iD, Joseph J Eron, Goran Bajic, Judith S Currier und 10 weitere

The Journal of Infectious Diseases · 15.11.2024 · 230 (5) · 1187-1196

DOI: 10.1093/infdis/jiae371 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 22.07.2024. Verfasst von Nathaniel Bloom und 21 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Innovation, La Jolla Institute for Immunology. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, COVID-19, Epitopes, B-Lymphocyte, Memory B Cells. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Collaborative Center for Human Immunology, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic monoclonal antibodies (mAbs) have been studied in humans, but the impact on immune memory of mAb treatment during an ongoing infection remains unclear. We evaluated the effect of infusion of the anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike receptor-binding domain (RBD) mAb bamlanivimab on memory B cells (MBCs) in SARS-CoV-2–infected individuals. Bamlanivimab treatment skewed the repertoire of MBCs targeting spike toward non-RBD epitopes. Furthermore, the relative affinity of RBD MBCs was weaker in mAb-treated individuals compared to placebo-treated individuals over time. Subsequently, after mRNA coronavirus disease 2019 vaccination, MBC differences persisted and mapped to a specific reduction in recognition of the class II RBD site, the same RBD epitope recognized by bamlanivimab. These findings indicate a substantial role of antibody feedback in regulating MBC responses to infection, and single mAb administration can continue to impact MBC responses to additional antigen exposures months later.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCOVID-19Epitopes, B-LymphocyteMemory B CellsSARS-CoV-2VaccinationFeedback, PhysiologicalAdultFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusAntibodies, Neutralizing

Stichwörter der Autor:innen

COVID-19SARS-CoV-2bamlanivimabmAb therapymemory B cells

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, ViralCOVID-19 VaccinesEpitopes, B-LymphocyteSpike Glycoprotein, CoronavirusbamlanivimabAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Center for Vaccine Innovation, La Jolla Institute for Immunology.
  • Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla.
  • Department of Microbiology.
  • Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania.
  • Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve School of Medicine, Cleveland, Ohio.

ORCID-Profile: Alex Greninger, Carlee Moser, Camila H Coelho

Förderung

  • NIAID NIH HHS
  • Collaborative Center for Human Immunology
  • NCI NIH HHS
  • A. P. Giannini Foundation
  • NIH Faculty Institutional Recruitment for Sustainable Transformation
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • La Jolla Institute for Immunology institutional funds

Zitieren

APA

Bloom, N., Ramirez, S. I., Cohn, H., Parikh, U. M., Heaps, A., Sieg, S. F., Greninger, A., Ritz, J., Moser, C., Eron, J. J., Bajic, G., Currier, J. S., Klekotka, P., Wohl, D. A., Daar, E. S., Li, J., Hughes, M. D., Chew, K. W., Smith, D. M., …, & Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team (2024). SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback. The Journal of Infectious Diseases, 230(5), 1187-1196. https://doi.org/10.1093/infdis/jiae371

Vancouver

Bloom N, Ramirez SI, Cohn H, Parikh UM, Heaps A, Sieg SF, et al. SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback. The Journal of Infectious Diseases. 2024;230(5):1187-1196. doi:10.1093/infdis/jiae371

BibTeX
@article{Bloom2024,
  author = {Bloom, Nathaniel and Ramirez, Sydney I and Cohn, Hallie and Parikh, Urvi M and Heaps, Amy and Sieg, Scott F and Greninger, Alex and Ritz, Justin and Moser, Carlee and Eron, Joseph J and Bajic, Goran and Currier, Judith S and Klekotka, Paul and Wohl, David A and Daar, Eric S and Li, Jonathan and Hughes, Michael D and Chew, Kara W and Smith, Davey M and Crotty, Shane and Coelho, Camila H and Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team, Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team},
  title = {SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody Feedback},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {230},
  number = {5},
  pages = {1187--1196},
  doi = {10.1093/infdis/jiae371}
}
Kostenlos starten →